| William Wade Peery, MD | |
|
3100 Tower Blvd, Ste 406, Durham, NC 27707-0034 | |
| (919) 287-3303 | |
| Not Available |
| Full Name | William Wade Peery |
|---|---|
| Gender | Male |
| Speciality | Surgery |
| Location | 3100 Tower Blvd, Durham, North Carolina |
| Accepts Medicare Assignments | Medicare enrolled and may accept medicare through third-party reassignment. May prescribe medicare part D drugs. |
| Identifier | Type | State | Issuer |
|---|---|---|---|
| 1093819161 | NPI | - | NPPES |
| 007374755 | Medicaid | VA | |
| VAA103996 | Other | MEDICARE # |
| Taxonomy | Type | License (State) | Status |
|---|---|---|---|
| 208600000X | Surgery | 0101029360 (Virginia) | Primary |
| 208600000X | Surgery | 200301509 (North Carolina) | Secondary |
| Entity Name | Dlp Twin County Physician Practices Llc |
|---|---|
| Entity Type | Part B Supplier - Clinic/group Practice |
| Entity Identifiers | NPI Number: 1962078527 PECOS PAC ID: 7214199512 Enrollment ID: O20120503000011 |
News Archive
In wound care treatment bandages and dressings may become archaic tools of the past. The future is in a spray called Youki that accelerates the healing process.
VIA Pharmaceuticals, Inc., a biotechnology company focused on the development of compounds for the treatment of cardiovascular and metabolic disease, today announced that on October 9, 2009, it received a determination letter from The NASDAQ Stock Market notifying the Company that the NASDAQ Hearing Panel (the "Panel") has granted the Company's request to remain listed on NASDAQ, subject to the Company demonstrating compliance with the NASDAQ Listing Rules (the "Listing Rules") on or before December 31, 2009 (the "Exception Period").
University of Pittsburgh and UPMC researchers are paving the way for genome-targeted treatments in pancreatic cancer, an especially deadly form of cancer with few existing therapeutic options, according to a pair of recent studies.
A University of Colorado Cancer Center study published in this month's Proceedings of the National Academy of Sciences describes the activity of a recently discovered communication molecule of the body's immune system, Interleukin 37 or IL-37. It has been known to limit inflammation and the current study reports its activity in the adaptive immune system: IL-37 inhibits the ability of the immune system to recognize and target new antigens.
As the coronavirus disease 2019 (COVID-19) pandemic approaches its eighteenth month, new variants of concern (VOCs) of the causative pathogen – severe acute respiratory syndrome coronavirus 2 (SARS-CoV-2) – continue to emerge all over the world. A new study explores the emergence of such VOCs among young children, below 12 years of age, and the potential consequences of this phenomenon.
› Verified 7 days ago
| Entity Name | Omnipoint Surgical Associates Llc |
|---|---|
| Entity Type | Part B Supplier - Clinic/group Practice |
| Entity Identifiers | NPI Number: 1306245162 PECOS PAC ID: 2668445982 Enrollment ID: O20150113000506 |
News Archive
In wound care treatment bandages and dressings may become archaic tools of the past. The future is in a spray called Youki that accelerates the healing process.
VIA Pharmaceuticals, Inc., a biotechnology company focused on the development of compounds for the treatment of cardiovascular and metabolic disease, today announced that on October 9, 2009, it received a determination letter from The NASDAQ Stock Market notifying the Company that the NASDAQ Hearing Panel (the "Panel") has granted the Company's request to remain listed on NASDAQ, subject to the Company demonstrating compliance with the NASDAQ Listing Rules (the "Listing Rules") on or before December 31, 2009 (the "Exception Period").
University of Pittsburgh and UPMC researchers are paving the way for genome-targeted treatments in pancreatic cancer, an especially deadly form of cancer with few existing therapeutic options, according to a pair of recent studies.
A University of Colorado Cancer Center study published in this month's Proceedings of the National Academy of Sciences describes the activity of a recently discovered communication molecule of the body's immune system, Interleukin 37 or IL-37. It has been known to limit inflammation and the current study reports its activity in the adaptive immune system: IL-37 inhibits the ability of the immune system to recognize and target new antigens.
As the coronavirus disease 2019 (COVID-19) pandemic approaches its eighteenth month, new variants of concern (VOCs) of the causative pathogen – severe acute respiratory syndrome coronavirus 2 (SARS-CoV-2) – continue to emerge all over the world. A new study explores the emergence of such VOCs among young children, below 12 years of age, and the potential consequences of this phenomenon.
› Verified 7 days ago
| Mailing Address | Practice Location Address |
|---|---|
| William Wade Peery, MD Po Box 15352, Belfast, ME 04915-4048 Ph: () - | William Wade Peery, MD 3100 Tower Blvd, Ste 406, Durham, NC 27707-0034 Ph: (919) 287-3303 |
News Archive
In wound care treatment bandages and dressings may become archaic tools of the past. The future is in a spray called Youki that accelerates the healing process.
VIA Pharmaceuticals, Inc., a biotechnology company focused on the development of compounds for the treatment of cardiovascular and metabolic disease, today announced that on October 9, 2009, it received a determination letter from The NASDAQ Stock Market notifying the Company that the NASDAQ Hearing Panel (the "Panel") has granted the Company's request to remain listed on NASDAQ, subject to the Company demonstrating compliance with the NASDAQ Listing Rules (the "Listing Rules") on or before December 31, 2009 (the "Exception Period").
University of Pittsburgh and UPMC researchers are paving the way for genome-targeted treatments in pancreatic cancer, an especially deadly form of cancer with few existing therapeutic options, according to a pair of recent studies.
A University of Colorado Cancer Center study published in this month's Proceedings of the National Academy of Sciences describes the activity of a recently discovered communication molecule of the body's immune system, Interleukin 37 or IL-37. It has been known to limit inflammation and the current study reports its activity in the adaptive immune system: IL-37 inhibits the ability of the immune system to recognize and target new antigens.
As the coronavirus disease 2019 (COVID-19) pandemic approaches its eighteenth month, new variants of concern (VOCs) of the causative pathogen – severe acute respiratory syndrome coronavirus 2 (SARS-CoV-2) – continue to emerge all over the world. A new study explores the emergence of such VOCs among young children, below 12 years of age, and the potential consequences of this phenomenon.
› Verified 7 days ago
Dr. Philip Walther, M.D. Surgery Medicare: Not Enrolled in Medicare Practice Location: 4101 N Roxboro St, Durham, NC 27704 Phone: 919-684-8111 | |
Hilliard F Seigler, MD Surgery Medicare: Not Enrolled in Medicare Practice Location: 508 Fulton St, Durham, NC 27705 Phone: 919-286-6939 | |
Dr. Andrew Serghios Barbas, MD Surgery Medicare: Accepting Medicare Assignments Practice Location: 2301 Erwin Rd, Dumc Box 3512, Durham, NC 27705 Phone: 919-684-8111 | |
Thomas D'amico, M.D. Surgery Medicare: Accepting Medicare Assignments Practice Location: 2100 Erwin Rd, Durham, NC 27710 Phone: 919-620-4467 | |
Dr. Howard Levinson, M.D. Surgery Medicare: Accepting Medicare Assignments Practice Location: 2100 Erwin Rd, Durham, NC 27710 Phone: 919-684-8111 | |
George Leight, M.D. Surgery Medicare: Not Enrolled in Medicare Practice Location: 2100 Erwin Rd, Durham, NC 27710 Phone: 919-620-4467 | |
Jeffrey Marcus, M.D. Surgery Medicare: Accepting Medicare Assignments Practice Location: 2100 Erwin Rd, Durham, NC 27710 Phone: 919-620-4467 |